KURA - クラ・オンコロジ― （Kura Oncology Inc.） クラ・オンコロジ―KURAのチャート
KURAの企業情報
| symbol | KURA |
|---|---|
| 会社名 | Kura Oncology Inc （クラ・オンコロジ―） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 クラ・オンコロジー(Kura Oncology Inc)は臨床段階のバイオ医薬品会社である。同社は固形腫瘍及び血液癌の治療のためのパーソナライズ治療薬の発見・開発に従事する。同社のセグメントは固形腫瘍及び血液癌の治療のためのパーソナライズ治療薬の発見・開発に従事する。同社は特定の癌の進行を促進する細胞シグナル伝達経路を標的とする小分子製品候補の開発に焦点を当てる。同社は固形腫瘍及び血液癌において、ファルネシルトランスフェラーゼ阻害剤であるチミファニブのリード製品候補を開発する。同社はマイトジェン活性化プロテインキナーゼ（MAPK）、シグナル伝達経路の変異または他の調節不全を有する腫瘍の患者に対する治療として、細胞外シグナル調節キナーゼ（ERK）の小分子阻害剤であるKO-947を促進して膵癌、結腸直腸癌、非小細胞肺癌（NSCLC）及びメラノーマを含む。 クラ・オンコロジ―は米国のバイオ医薬品企業。臨床ステ―ジで、固形腫瘍がんや血液がんの患者に対してカスタマイズされた治療法を開発する。同社が焦点を当てるパイプラインには、特定のがんの進行をつかさどる細胞シグナリング経路をタ―ゲットにする小分子医薬品を含む。本社はカリフォルニア州ラホヤ。 Tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase in-licensed from Janssen. Previously, tipifarnib was studied in more than 5,000 cancer patients and showed compelling and durable anti-cancer activity in certain patient subsets; however, no molecular mechanism of action had been determined that could explain its clinical activity across a range of solid tumor and hematologic indications. Leveraging advances in next generation sequencing as well as emerging information about cancer genetics and tumor biology, the Company is seeking to identify those patients most likely to benefit from tipifarnib. In addition to Breakthrough Therapy Designation, tipifarnib has been granted Fast Track designation by the FDA for the treatment of patients with HRAS mutant HNSCC. In addition to HNSCC, tipifarnib has demonstrated encouraging clinical activity in a number of additional genetically defined tumor types. Kura has received multiple issued patents for tipifarnib, providing patent exclusivity in the U.S. and foreign countries. About Kura Oncology |
| 本社所在地 | 3033 Science Park Road Suite 220 San Diego CA 92121 USA |
| 代表者氏名 | Troy E. Wilson トロイE.ウィルソン |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer Principal Accounting Officer |
| 電話番号 | +1 858-500-8800 |
| 設立年月日 | 39387 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | － |
| url | www.kuraoncology.com |
| nasdaq_url | https://www.nasdaq.com/symbol/kura |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -50.73800 |
| 終値（lastsale） | 15.77 |
| 時価総額（marketcap） | 598870512.54 |
| 時価総額 | 時価総額（百万ドル） 546.08480 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 427.16280 |
| 当期純利益 | 当期純利益（百万ドル） -49.42400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Kura Oncology Inc revenues was not reported. Net loss increased 91% to $29.3M. Higher net loss reflects General and administrative - Balancing v increase of 51% to $5.5M (expense) Share-based compensation increase from $1.3M to $2.8M (expense) Stock-based Compensation in SGA increase from $658K to $1.6M (expense). |
KURAのテクニカル分析
KURAのニュース
Can you now get a good deal on Kura Oncology Inc.’s shares? 2023/03/10 12:54:00 US Post News
Kura Oncology Inc. (NASDAQ:KURA) marked $11.04 per share on Thursday, down from a previous closing price of $11.08. While Kura Oncology Inc. has underperformed by -0.36%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KURA fell by -32.35%, with highs and lows ranging from $19.93 to […]
The Kura Oncology Inc. (KURA) had a good session last reading, didn’t it? 2023/03/02 16:54:00 US Post News
A share of Kura Oncology Inc. (NASDAQ:KURA) closed at $11.95 per share on Wednesday, up from $11.92 day before. While Kura Oncology Inc. has overperformed by 0.25%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KURA fell by -24.70%, with highs and lows ranging from $19.93 […]
Kura Oncology to Participate in Upcoming Investor Conferences 2023/03/01 12:30:00 GlobeNewswire
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences:
Kura Oncology drops multiple clinical programs for J&J-discovered tipifarnib 2023/02/24 16:01:09 Endpoints News
Kura Oncology is axing all but one clinical development program involving an old Janssen candidate. According to an SEC filing on Thursday, Kura has dropped multiple programs for tipifarnib, a farnesyltransferase inhibitor (FTI) that targets a protein called HRAS. The drug was originally discovered by J&J, which handed it off
Kura Oncology, Inc. (KURA) Q4 2022 Earnings Call Transcript 2023/02/24 03:11:19 Seeking Alpha
Kura Oncology, Inc. (NASDAQ:NASDAQ:KURA) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ETCompany ParticipantsPete De Spain - Senior Vice President of Investor Relations and…
Kura Oncology to Participate in Upcoming Investor Conferences 2023/03/01 12:30:00 GlobeNewswire
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences:
Kura Oncology drops multiple clinical programs for J&J-discovered tipifarnib 2023/02/24 16:01:09 Endpoints News
Kura Oncology is axing all but one clinical development program involving an old Janssen candidate. According to an SEC filing on Thursday, Kura has dropped multiple programs for tipifarnib, a farnesyltransferase inhibitor (FTI) that targets a protein called HRAS. The drug was originally discovered by J&J, which handed it off
Kura Oncology, Inc. (KURA) Q4 2022 Earnings Call Transcript 2023/02/24 03:11:19 Seeking Alpha
Kura Oncology, Inc. (NASDAQ:NASDAQ:KURA) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ETCompany ParticipantsPete De Spain - Senior Vice President of Investor Relations and…
Kura Oncology: Q4 Earnings Snapshot 2023/02/23 21:27:11 WTOP
SAN DIEGO (AP) — SAN DIEGO (AP) — Kura Oncology Inc. (KURA) on Thursday reported a loss of $33.1 million…
Kura Oncology GAAP EPS of -$0.49 beats by $0.08 2023/02/23 21:23:45 Seeking Alpha
Kura Oncology press release (KURA): Q4 GAAP EPS of -$0.49 beats by $0.08.$438 million in cash, equivalents and investments provide runway into fourth quarter of 2025
Kura Oncology Inc. (NASDAQ: KURA) Jumps 1.31%: What Could Be On The Way Going Forward? 2022/12/31 17:00:00 Stocks Register
Kura Oncology Inc. (NASDAQ:KURA) shares, rose in value on Friday, 12/30/22, with the stock price up by 1.31% to the previous day’s close as strong demand from buyers drove the stock to $12.41. Actively observing the price movement in the last trading, the stock closed the session at $12.25, falling within a range of $11.86 … Kura Oncology Inc. (NASDAQ: KURA) Jumps 1.31%: What Could Be On The Way Going Forward? Read More »
KURA stock falls SNDX stock gains after Phase 1/2 data for leukemia drugs (NASDAQ:KURA) 2022/12/12 18:34:01 Seeking Alpha
Kura Oncology (KURA) slumped and Syndax Pharmaceuticals (SNDX) climbed after Phase 1/2 trial for their respective myeloid leukemia candidates. Read the full story here.
Kura Oncology Shares Fall After Updated Ziftomenib Data At ASH Meeting 2022/12/12 16:34:20 Benzinga
Kura Oncology Inc (NASDAQ: KURA ) announced updated clinical data from the KOMET-001 Phase 1/2 trial of ziftomenib in patients with relapsed/refractory acute myeloid leukemia (AML). Ziftomenib demonstrated optimal clinical benefit at 600 mg with a 30% CR rate (6/20) in patients with NPM1-mutant AML, compared to 17% (1/6) at 200 mg. Notably, four NPM1-mutant patients who achieved a CR at 600 mg … Full story available on Benzinga.com
Kura Oncology Inc. (NASDAQ: KURA) Drops -24.56% From Highs, What Happens Next? 2022/12/03 12:00:00 Marketing Sentinel
Kura Oncology Inc. (NASDAQ:KURA)’s traded shares stood at 0.81 million during the last session, with the company’s beta value hitting 0.84. At the close of trading, the stock’s price was $16.00, to imply an increase of 2.76% or $0.43 in intraday trading. The KURA share’s 52-week high remains $19.93, putting it -24.56% down since that … Kura Oncology Inc. (NASDAQ: KURA) Drops -24.56% From Highs, What Happens Next? Read More »